The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

We recently published

Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer.

Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as it upgraded the shares to Outperform from Market Perform and raised the share price target to $265 from $252. The financial firm commented that Johnson & Johnson (NYSE:JNJ)’s new drugs will inject momentum into the firm’s revenue growth and share price performance. Cramer has also discussed the firm’s drugs on several occasions over the past couple of months. For instance, in his Mad Money appearance on May 29th, the CNBC TV host compared Johnson & Johnson (NYSE:JNJ) to Merck and commented that “Merck’s cancer dominance has been challenged of late by JNJ.” In this tweet, he commented on the firm’s recent share price performance, which has seen Johnson & Johnson (NYSE:JNJ)’s shares gain 7.7% over the past month, in the context of illiquidity in the market:

“illiquidity =insane health care gains like Cardinal and JNJ”

Emilio100 / Shutterstock.com

Here is what Cramer said about Johnson & Johnson (NYSE:JNJ) on his April 24th appearance on Mad Money:

“Yeah, David, they’re hitting the pharma again, they’re killing healthcare. JNJ, one of the foremost companies of this country, 19 times earnings, down very badly. I don’t think it ends yet because this is a huge trade, out of healthcare, into semis and it’s really interesting because as you go out of a huge part of the market into a very concentrated area, tends not to act, tends not to be a good idea but people are doing it. I say look at the bargains in healthcare, some of the companies are going to come back and you’re going to regret that you sold them.”

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.  Disclosure: None. Follow Insider Monkey on Google News.